Epistemis

Integration and Clinical Practice

  • Integrated Analysis, Clinical Cases and Adjustment Algorithms

This module integrates the respiratory drugs reviewed through an analytical synthesis and a therapeutic decision-making map based on global reference guidelines (GINA and GOLD).

File

Biophysics of inhalation devices

The selection of the inhalation device is as decisive for clinical efficacy as the molecule prescribed:

  • Pressurized Metered Dose Inhalers (pMDI): They require close coordination between manual triggering and slow, deep inspiration. In the elderly, children and patients with cognitive impairment, the combined use of a spacer chamber is mandatory to reduce oropharyngeal impaction of the drug and optimize pulmonary alveolar deposition.
  • Dry Powder Inhalers (DPI): These are devices activated by the patient's own inspiratory flow. They require a minimum inspiratory flow from the patient (30 - 60 L/min) to generate the physical turbulence that dissociates the drug microparticles transported in lactose. They are contraindicated in severe crises or severe acute exacerbations due to the patient's inability to breathe forcefully.
  • Soft Mist Inhalers (SMI - Respimat): They release the drug using mechanical energy (a spring) generating a slow cloud with very low oropharyngeal impact and excellent pulmonary deposition independently of the patient's effort.

Reference Pharmacological Synthesis Table

Active Drug Cellular Target / Mechanism Clinical Danger / Major Alert Relevance Dose Adjustment
Salbutamol Selective β2-adrenergic receptor agonist Severe hypokalemia, cardiac arrhythmias in overdose. No changes in the usual inhalation route.
Formoterol Selective β2 agonist with rapid onset and long duration Prohibited to be used as monotherapy in asthma. Always associate ICS with asthma permanently.
Tiotropium Cholinergic antagonist with M3 kinetic selectivity Urinary retention, dry mouth, narrow angle glaucoma. Monitor closely if renal clearance is <50 mL/min.
Budesonide / Fluticasone Nuclear transrepression of the proinflammatory factor NF-κB Recurrent oropharyngeal candidiasis, pneumonia in COPD. Mandatory post-inhalation mouthwash.
Theophylline PDE inhibition and HDAC2 stimulation at low doses Severe arrhythmias, seizures. Narrow therapeutic margin. Reduce by 50% with CYP1A2 inhibitors.
Montelukast Competitive antagonist of the CysLT1 receptor Serious neuropsychiatric effects (Black Box FDA). No changes due to mild kidney or liver function.
Omalizumab Humanized free IgE neutralizing antibody Delayed systemic anaphylaxis reaction. Mandatory adjustment for weight and basal IgE level.
Benralizumab ADCC cell destruction of eosinophils via NK Transient headache, mild pharyngitis. Monthly fixed dose (every 8 weeks for maintenance).
Nintedanib Competitive multikinase inhibitor of VEGFR/PDGFR/FGFR Severe untreatable diarrhea, liver toxicity. Contraindicated in Child-Pugh B or C liver failure.

Gold summary in Respiratory Therapeutics

Three cross-cutting clinical principles should guide the prescription of active respiratory drugs:

  1. The priority of the inhalation route: The inhaled route should always be preferred over the systemic route for local control of the airway, as it maximizes cell concentration in the target organ and minimizes systemic side effects of any kind.
  2. GINA Dynamic Approach for Asthma: Asthma is treated through therapeutic steps by increasing or decreasing the dose of ICS according to symptomatic control and previous exacerbations, maintaining ICS/Formoterol as the preferred Track 1 mainstay.
  3. Continuous maintenance in COPD: Unlike asthma attacks, patients with COPD require persistent maintenance bronchodilation with LAMA or LAMA/LABA to prevent accelerated loss of lung function and hospitalizations.

Pharmacological criteria and understanding of the cellular interaction of the drug in the alveolus are decisive in mitigating bronchospasm crises and slowing down chronic tissue remodeling in respiratory patients.

Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.

PreviousNintedanib and Pirfenidone
System
Respiratory
Cluster
Integrated Analysis, Clinical Cases and Adjustment…
Download Epistemis